GlassScriptPhysician profile
Jessica Lo
NPI 1700228426
$2,097.20
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $485 · 2021: $584.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $395.51 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $354.24 | 2019-2021 | |
| Allergan, INC. | $283.28 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $259.98 | 2019-2021 | |
| Glaukos Corporation | $193.17 | 2019 | |
| Shire North American Group INC | $178.50 | 2019 | |
| Eyevance Pharmaceuticals LLC | $144.63 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $133.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $115.51 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $39.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.